Previous 10 | Next 10 |
Hoth Therapeutics (HOTH) soars 56% premarket after announcing new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002, a novel therapeutic targeted for the treatment of COVID-19. The lead HT-002 peptide candidate was shown to inhi...
Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19 Therapeutic PR Newswire NEW YORK , March 23, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrat...
Hoth Therapeutics to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 Robb Knie, CEO, will also participate in a panel discussion entitled, 'Coming Together to Address Unmet Medical Needs' PR Newswire NEW YORK , March 22, 2021 /PRNewswir...
Hoth Therapeutics CEO, Robb Knie, Featured on the RedChip Money Report on Bloomberg TV this Saturday, March 20th PR Newswire NEW YORK , March 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical...
Hoth Therapeutics (HOTH) announces entering into a Research Agreement with the University of Cincinnati Research Institute ("UCRI") to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.HT-006 is a novel antibiot...
Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006 PR Newswire NEW YORK , March 17, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical ...
Microcap Hoth Therapeutics (HOTH) has signed an agreement with contract research organization REPROCELL Ltd. to evaluate the HT-003 platform on tissue from ulcerative colitis and Crohn's patients.Hoth says that HT-003's active pharmaceutical ingredient is an inhibitor of retinoic acid metabol...
Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease PR Newswire NEW YORK , March 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, ...
Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Hoth's Largest Shareholder Agrees to One Year Lockup PR Newswire NEW YORK , March 10, 2021 /PRNewswire/ -- Hoth Therapeutics, I...
ACADIA Pharmaceuticals (ACAD) -45% after suffers setback in label expansion application for Pimavanserin.Stitch Fix (SFIX) -22% on FQ2 earnings release.Waitr Holdings (WTRH) -16% on Q4 earnings release.DICK'S Sporting Goods (DKS) -6% on Q4 earnings rele...
News, Short Squeeze, Breakout and More Instantly...
Hoth Therapeutics Inc. Company Name:
HOTH Stock Symbol:
NASDAQ Market:
Hoth Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment PR Newswire Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitiv...